DNA Sequencing Market

Increased technological advancement to boost the market growth

DNA sequencing technology can sequence multiple DNA strands through massive parallelization. Such sequencing includes Sanger sequencing and non-Sanger sequencing. Compared with microarrays and other genomic analysis methods, DNA sequencing has the advantages of low cost, high accuracy, high speed, and precise results, even with small sample input volumes. DNA sequencing is used to perform a variety of applications, such as biomarker discovery, oncology research, personalized medicine, forensics, and more. It simplifies nucleotide analysis and is a broad alternative to traditional genomics tools, notably microarrays, genotyping, and more.

The demand for DNA sequencing has increased significantly owing to the proliferation of sequencing applications and the increase in technological advancements in DNA sequencing. Moreover, the surge in genome mapping initiatives and increasing investment in research and development across the globe drive market growth.

DNA sequencing has brought about a paradigm shift in proteomics and genomics research. It is a highly accurate and high-throughput technology used in various applications such as de novo assembly, WGS, and DNA resequencing. Therefore, the technology is quickly adopted by several academic research institutions for research. Illumina installed the NovaSeq 6000 Sequencing System at the Whitehead Biomedical Research Institute in Massachusetts, USA, in June 2020.

The market of DNA sequencing is driven by efforts by the Centers for Medicare & Medicaid Services (CMS), the Society for Molecular Pathology, and commercial payers such as Blue Cross Blue Shield and Aetna to facilitate the clinical use of sequencing technology. For example, in January 2020, China Medical System expanded the coverage of NGS-based diagnostic tests for ovarian and breast cancer patients, providing patients with more opportunities for personalized cancer care. Therefore, the market CAGR of DNA Sequencing has been increasing globally in recent years. These are essential factors driving the DNA Sequencing market revenue growth.

The sequencing of DNA is a method that uses extensive parallelization to sequence many DNA strands. Both Sanger's technique and non-Sanger methods of sequencing are used in this sequencing. The development of pharmacological treatments for cancer is accelerated by individualized targeted sequencing of tumors, which also discovers cancer targets or pathways. Introducing large-scale initiatives utilizing NGS techniques produces a fresh fundamental understanding of oncology precision therapy. Compared to microarray and other genetic analysis methods, DNA sequencing offers advantages such as excellent accuracy & speed, cheap cost, and accurate results even with limited sample input.

Biomarker identification, forensic analysis, oncology research, and individualized healthcare are among the uses for DNA sequencing.

It has greatly outperformed more traditional genomics methods, including genotyping, microarray, and others, and has sped up the study of nucleotides. DNA sequencing, a highly accurate and high-throughput technology utilized for various applications, including WGS, de novo assembly, and DNA resequencing, has caused an upheaval in proteomic and genomic studies. As a result, several academic research institutions can utilize this technology for research investigations. Consumer call for DNA sequencing has significantly increased due to the surge in sequencing applications and growth in DNA sequencing technology. Additionally, a boost in worldwide genome mapping efforts and R&D spending drive the market's expansion.

Technology advancements in DNA sequencing, increased clinical diagnostics and drug development applications, and higher R&D spending influence market growth. Applications for DNA sequencing can be found in forensics, personalized medicine, biomarkers, reproductive health, and other fields. DNA sequencing technology has enormous potential in clinical research and development for cancer diagnostics and therapies. The ability of NGS, or next-generation sequencing, to find and characterize clinically relevant genetic variations across several genes in a single test has recently been established quickly and affordably.

In June 2024: Roche announced a strategic partnership with a leading bioinformatics company to enhance DNA sequencing data analysis capabilities.

In November 2023, Illumina, Inc. unveiled its Global Health Access Initiative to improve the access to sequencing tools used in public health by poor nations. PacBio has entered into an agreement to acquire Apton Biosystems by August 2023. The takeover is expected to fasten short-read sequencer development, prompting the market growth

The Global DNA Sequencing Market Industry experiences a notable surge in demand for personalized medicine, driven by advancements in genomics and biotechnology. As healthcare shifts towards tailored treatments, DNA sequencing plays a pivotal role in identifying genetic variations that influence drug responses. This trend is underscored by the projected market value of 15.6 USD Billion in 2024, reflecting the growing integration of genomic data in clinical practices. Furthermore, the increasing prevalence of genetic disorders necessitates precise diagnostic tools, thereby propelling the adoption of DNA sequencing technologies. The emphasis on personalized healthcare solutions is likely to sustain growth in the Global DNA Sequencing Market Industry.

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. North American DNA Sequencing market, which accounted for USD 1.05 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Continuous technological development by major players, high investment in R&D, and availability of technologically advanced healthcare infrastructure have led North America to hold a leading market share in the DNA sequencing. Several government initiatives in the United States and Canada support drug development and cancer treatment research.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 DNA SEQUENCING MARKET SHARE BY REGION 2023 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's DNA Sequencing market accounts for the second-largest market share. Increasing adoption of organic growth strategies, such as product launches by key players in the Region to expand product portfolios, is expected to drive market growth over the forecast period. For example, in December 2021, Swiss-based pharmaceutical company F. Hoffmann-La Roche Ltd announced the launch of the AVENIO Edge System to provide a fully automated, integrated sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that provides integrated end-to-end control and reliable, consistently high-quality results.

Further, the German market of DNA Sequencing held the largest market share, and the U.K. market of DNA Sequencing was the fastest-growing market in the European Region.

The Asia-Pacific DNA Sequencing Market is expected to grow at the fastest CAGR from 2024 to 2032. A growing customer base drives international companies to expand their business through strategic moves. A prominent California company has raised over $75 million to expand its desktop DNA sequencers to support the ongoing crisis of COVID-19. Moreover, the China market of DNA Sequencing held the largest market share, and the Indian market of DNA Sequencing was the fastest-growing market in the Asia-Pacific region.

Major market players are spending a lot on R&D to increase their product lines, which will help the market of DNA Sequencing grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the DNA Sequencing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the DNA Sequencing industry to benefit clients and expand the market sector. The DNA Sequencing industry has provided medicine with some of the most significant benefits in recent years. In the market of DNA Sequencing, major players such as Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Cardiva Medical Inc., Morris Innovative Inc., and others are working on expanding the market demand by investing in research and development activities.

Illumina, Inc. is an American biotechnology company headquartered in San Diego, California, serving over 140 countries. Illumina was founded on April 1, 1998, to develop, manufacture, and sell integrated systems to analyze genetic variation and biological function. The company offers a range of products and services for sequencing, genotyping, gene expression, and proteomics. On January 9, 2023, pharmaceutical company Illumina Inc. and Nashville Biosciences LLC, a wholly owned Vanderbilt University Medical Center (VUMC) subsidiary, announced an agreement with biopharmaceutical company Amgen to sequence the whole genome of DNA samples of approximately 35,000 samples.

The protocol helps accelerate therapeutic development through genomics and builds superior clinical genomic datasets.

Also, F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company with two divisions Pharmaceuticals and Diagnostics. The shares of its holding company, Roche Holding AG, are listed on the six major Swiss exchanges. The company is headquartered in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the world's leading provider of cancer treatments. In May 2020, F. Hoffman-La Roche Ltd. announced the acquisition of Stratos Genomics to advance the development of Roche nanopore sequencers. Roche believes the acquisition helps address clinical research needs and, thus, patient needs.